Middle East Pharmaceutical Industries Company (TADAWUL:4016)

Market Cap	2.27B -13.0%
Revenue (ttm)	458.96M +18.5%
Net Income	97.29M +20.9%
EPS	4.86 +20.9%
Shares Out	20.00M
PE Ratio	23.35
Forward PE	19.79
Dividend	2.50 (2.17%)
Ex-Dividend Date	Sep 2, 2025

Volume	32,650
Average Volume	66,772
Open	115.00
Previous Close	115.40
Day's Range	113.10 - 115.30
52-Week Range	108.00 - 140.60
Beta	0.73
RSI	52.99
Earnings Date	Mar 26, 2026

About TADAWUL:4016

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. Its product portfolio includes dermatological, respiratory, cardiovascular, alimentary and anti-infectives, musculoskeletal, genitourinary systems, and CNS. The company also exports its products. Middle East Pharmaceutical Industries Company was formerly known...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 632
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4016

Financial Performance

In 2024, TADAWUL:4016's revenue was 394.00 million, an increase of 16.42% compared to the previous year's 338.44 million. Earnings were 79.85 million, an increase of 21.30%.